Covid-19 and Semi-Periphery

Argentina and the Global Vaccines Research and Development

Authors

  • Daniel Blinder National Scientific and Technical Research Council (CONICET) https://orcid.org/0000-0002-9318-7040
  • Lautaro Zubeldía National University of José Clemente Paz
  • Sofya Surtayeva National University of San Martín

DOI:

https://doi.org/10.5195/jwsr.2021.1049

Keywords:

geopolitics, semi-periphery, global value chains, vaccines, Covid-19, Big Pharma

Abstract

The  SARS-CoV-2 pandemic  has disturbed the order of the world-system. While central countries—through their pharmaceutical multinationals—focused on the development of  vaccines, semi-peripheral and peripheral countries fulfill another role, either by offering an environment for trials, or by inserting themselves in the hierarchical global order as a hub for research, development, or production of the candidate vaccines. This paper focuses on the analysis of the geopolitics of the world-system regarding production and participation in the clinical trials of vaccines for SARS-CoV-2 of Oxford University-AstraZeneca, BioNTech-Pfizer, and Sinopharm in Argentina. This is a case analysis of the Argentine semi-peripheral context, the local and global pharmaceutical industry, and the geopolitical order. We conclude that Argentina, which has scientific and industrial capabilities to manufacture vaccines, has joined in global value chains on the dependence side, deepening the scientific and technological gap vis-à-vis the central countries.

Author Biographies

Daniel Blinder, National Scientific and Technical Research Council (CONICET)

Daniel Blinder is a political scientist, researcher at the National Scientific and Technical Research Council (CONICET), and professor at the National University of José Clemente Paz, Argentina, specializing in International Relations and Geopolitics of technology, Space Policy, and National Defense.

Lautaro Zubeldía, National University of José Clemente Paz

Lautaro Zubeldia-Brenner is a molecular biologist, researcher at the José Babini Center for the Study of History of Science and Technology of National University of San Martín, Argentina, and professor at National University of José Clemente Paz, specializing in science and technology management, vaccine and medicine industry and public health.

Sofya Surtayeva, National University of San Martín

Sofya Surtayeva is researcher at the José Babini Center for the Study of History of Science and Technology, National University of San Martín, Argentina. She specializes in Latin American Science and Technology Policy

References

Agnew, John and Corbridge, Stuart. 1995. Mastering Space: Hegemony, Territory and International Political Economy. New York: Routledge.

Angell, Marcia. 2004. The Truth About the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House Trade Paperbacks.

AstraZeneca. 2020. “COVID-19 vaccine AZD1222 clinical trials resumed in the UK”. September 12. Retrieved October 13, 2020 (https://www.astrazeneca.com/media-centre/press-releases/2020/covid-19-vaccine-azd1222-clinical-trials-resumed-in-the-uk.html)

Babones, Salvatore. 2005. “The Country-Level Income Structure of the World-Economy.” Journal of World-Systems Research 11(1):29-55.

BAE Negocios. 2020a. “China busca probar su vacuna en Argentina”, August 19. Retrieved September 16, 2020 (https://www.baenegocios.com/sociedad/China-busca-probar-su-vacuna-en-Argentina--20200819-0016.html)

_____. 2020b. “Formalizaron el acuerdo para las pruebas de la vacuna china”, August 22. Retrieved September 16, 2020 (https://www.baenegocios.com/sociedad/Formalizaron-el-acuerdo-para-las-pruebas-la-vacuna-china-20200822-0011.html)

Branson, William and Hanna, Naggy. 2000. “Ownership and Conditionality. OED Working Paper Series No. 8”. Washington: World Bank. Retrieved July 1, 2021 (https://ieg.worldbankgroup.org/sites/default/files/Data/reports/ownrshp.pdf)

Centenera, Mar. 2021. “Argentina reclama a Rusia por la demora en la entrega de la vacuna Sputnik V”, El País, July 22. Retrieved July 22, 2021 (https://elpais.com/internacional/2021-07-22/argentina-reclama-a-rusia-por-la-demora-en-la-entrega-de-la-vacuna-sputnik-v.html)

Chang, Ha-Joon, Cheema, Ali and Mises, L. 2002. “Conditions For Successful Technology Policy In Developing Countries—Learning Rents, State Structures, And Institutions.” Economics of Innovation and New Technology 11(4-5):369-398. doi:10.1080/10438590200000005

Chase-Dunn, Christopher. 1998. Global Formation. Structures of the World-Economy, Updated Edition. Oxford: Rowman & Littlefield Publishing.

Chena, Pablo I., Buccella, Emilia and Bosnic Carolina. 2018. “Efectos de la financierización en el cambio tecnológico en América Latina.” Pp. 95-139 in Estudios sobre financierización en América Latina, edited by Martín Abeles, Pérez Caldentey Esteban and Valdecantos Sebastián. Santiago: Comisión Económica para América Latina y el Caribe.

Clelland, Donald. 2014. “The Core of the Apple: Degrees of Monopoly and Dark Value in Global Commodity Chains.” Journal of World-Systems Research, 20(1):82-111. https://doi.org/10.5195/jwsr.2014.564

Coriat, Benjamin, Fabienne Orsi, and Olivier Weinstein. 2003. “Does Biotech Reflect a New Science-based Innovation Regime?” Industry and Innovation 10(3):231-253. doi:10.1080/1366271032000141634

Coriat, Benjamin and Weinstein, Olivier. 2011. “Patent regimes, firms and the commodification of knowledge.” Socio-economic Review 10(2):267-292.

Correa, Carlos. 1997. “Instrumentación del acuerdo TRIPS en Latinoamérica. Armonización vs. Diferenciación de los sistemas de propiedad intelectual”, Temas de Derecho Industrial y de la Competencia, No.1.

Corvalán, Dora. 2010. “Estudios sobre los Desarrollos Internacionales de la Biotecnología Industrial: Vacunas Humanas”, CEUR-CONICET.

_____. 2017. “Des-Aprendizaje y Pérdida de Capacidades Locales. El Calendario Nacional de Vacunación en Argentina.” Ciencia, Docencia y Tecnología 28(54):1-37.

Coy, Peter. 2020. “The Road to a Coronavirus Vaccine Runs Through Oslo.” Bloomberg, February 13. Retrieved September 16, 2020 (https://www.bloomberg.com/news/articles/2020-02-13/this-oslo-facility-may-be-the-key-to-the-coronavirus-vaccine)

Cunzolo, Florencia. 2020. “Buscan 3.000 voluntarios para probar otra vacuna contra el coronavirus en Argentina: cómo postularse.” Clarín, September 8. Retrieved September 16, 2020 (https://www.clarin.com/buena-vida/buscan-3-000-voluntarios-probar-vacuna-coronavirus-argentina-postularse_0_3V45uA2F9.html)

Dallas, Mark P., Ponte, Stefano and Sturgeon, Timothy J. 2019. “Power in global value chains.” Review of International Political Economy 26(4):666–694. doi:10.1080/09692290.2019.1608284.

Danneels, Erwin. 2012. “Second-order competences and Schumpeterian rents.” Strategic Entrepreneurship Journal 6(1):42-58. doi:10.1002/sej.1127

Davies, Madlen, Furneaux, Rosa, Canbral, Ernesto, Langlois, Jill, Ruíz, Iván, Amancio, Nelly. 2021. “Las exigencias de Pfizer: piden a gobiernos utilizar activos soberanos como garantía para acuerdo de vacuna”. February 23. In: https://ojo-publico.com/2502/las-abusivas-exigencias-de-pfizer-con-las-vacunas-covid-19. Retrieved March 3, 2021.

Davis, Dennis, Kaplinsky, Raphael and Morris, Mike. 2018. “Rents, Power and Governance in Global Value Chains.” Journal of World-Systems Research 24(1):43-71. https://doi.org/10.5195/jwsr.2018.662

Delvenne, Pierre, Vasen, Federico and Vara, Ana María. 2013. “The “soy-ization” of Argentina: The dynamics of the “globalized” privatization regime in a peripheral context.” Technology in Society 35(2):153–162. doi:10.1016/j.techsoc.2013.01.005

Díaz, Ileana I. and Mountz, Alison. 2020. “Intensifying Fissures: Geopolitics, Nationalism, Militarism, and the US Response to the Novel Coronavirus.” Geopolitics 25(5):1-8. doi:10.1080/14650045.2020.1789804

Disposal ANMAT. 2020a. Number DI-2020-5200-APN-ANMAT#MS

_____. 2020b. Number DI-2020-6087-APN-ANMAT#MS

Dunford, Michael and Qi, Bing. 2020. “Global reset: COVID-19, systemic rivalry and the global order.” Research in Globalization. Retrieved November 16, 2020 (https://doi.org/10.1016/j.resglo.2020.100021)

ENDEI II. 2020. “Sector manufacturero.” Ministerio de Ciencia Tecnología e Innovación productiva. Retrieved October 16, 2020 (https://www.argentina.gob.ar/sites/default/files/infografia_endei_ii_-_industria_manufacturera_0.pdf)

Esteban, Pablo. 2020a. “Vacuna de Oxford: ¿cómo se fabricará en Argentina?”, Página 12, August 15. Retrieved September 16, 2020 (https://www.pagina12.com.ar/285000-vacuna-de-oxford-como-se-fabricara-en-argentina)

_____. 2020b. “Coronavirus: ¿Qué vacunas podrían llegar a las personas primero?”, Página 12, August 23. Retrieved September 16, 2020 (https://www.pagina12.com.ar/286947-coronavirus-que-vacunas-podrian-llegar-a-las-personas-primer)

Evans, Peter. 1979. Dependent Development. The Alliance of Multinational, State, and Local Capital in Brazil. New Jersey: Princeton University Press.

Fernández P., María, López T., José, A., Bayas, José. M. and Cambronero, María. 2020. “Quo vadis en vacunas: desde la aproximación empírica a la nueva oleada tecnológica.” Revista española de geriatria y gerontologia 55(3):160-168.

Flint, Colin and Taylor, Peter. 2018. Political Geography: World-Economy, Nation-State and Locality. London: Routledge.

Folegatti, Pedro, M., Ewer, Katie, J., Aley, Parvinder K., Angus, Brian, Becker, Stephan, Belij Rammerstorfer, Sandra, et al. 2020. “Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.” The Lancet 396(10249):467-478, Retrieved July 20, 2020 (https://doi.org/10.1016/S0140-6736(20)31604-4)

Foundation Huésped. 2020. “Sobre las fuentes de financiamiento de Fundación Huésped”. Retrieved October 16, 2020 (https://www.huesped.org.ar/noticias/sobre-las-fuentes-de-financiamiento-de-fundacion-huesped/)

Foundation Infant. 2020. Retrieved October 16, 2020 (https://www.infant.org.ar/)

Gadelha, Carlos A., Costa, Patricia, Mattoso, Karla and Cesário, Bernardo. 2020. “Acesso a vacinas no Brasil no contexto da dinâmica global do Complexo Econômico-Industrial da Saúde.” Cadernos de Saúde Pública 36(2):1-17.

Gambardella, Alfonso. 1995. Science and Innovation: The US Pharmaceutical Industry in the 1980s. Cambridge University Press: Cambridge.

GAVI. 2020. Retrieved October 9, 2020 (https://www.gavi.org/)

_____. 2021. Retrieved March 3, 2021 (https://www.gavi.org/vaccineswork/covax-explained)

Gereffi, Gary and Korzeniewicz, Miguel. 1990. “Commodity Chains and Footwear Exports in the Semiperiphery”. Pp. 45-68 in: Semiperipheral States in the World-Economy, edited by Martin, William. New York: Greenwood Press.

Gouglas, Dimitrios, Christodoulou, Mario, Plotkin., Stanley A. and Hatchett Richard. 2019. “CEPI: Driving Progress Towards Epidemic Preparedness And Response.” Epidemiologic Reviews 41(1):28-33.

Govindaraj, Ramesh, Reich, Michael and Cohen, Jillian. 2000. “World Bank Pharmaceuticals”. Health, Nutrition and Population (HNP) Discussion Paper. Washington DC: World Bank.

Greco, Michel. 2004. “Development and Supply of Vaccines: An Industry Perspective.” Pp. 75-89 in New generation vaccines, edited by Levine, Myron M. New York: London: Marcel Dekker; Taylor & Francis.

Gutiérrez, Íciar. 2020. “Una cuarta parte de la población mundial no recibirá la vacuna COVID hasta al menos 2022 tras el acopio de dosis de los países ricos”, El Diario.Es. December 17. Retrieved December 17, 2020 (https://www.eldiario.es/internacional/expertos-temen-cuarto-poblacion-mundial-no-reciba-vacuna-covid-2022_1_6510275.html)

Gutman, Graciela and Lavarello, Pablo. 2014. Biotecnología industrial en Argentina: estrategias empresariales frente al nuevo paradigma. Buenos Aires: Gran Aldea Editores.

Hall, Thomas and Chase-Dunn, Christopher. 2006. “Global Social Change in the Long Run.” Pp. 33-58 in Global Social Change. Historical and Comparative Perspectives, edited by Christopher Chase-Dunn y Salvatore Babones. Baltimore: The Johns Hopkins University Press.

Hecht, Gabrielle. 2009. The Radiance of France: Nuclear Power and National Identity after World War II. Massachusetts: MIT Press.

Hooker, Lucy and Palumbo, Daniele. 2020. “Covid vaccines: Will drug companies make bumper profits?”, BBC Bussines, December 18. Retrieved December 18, 2020 (https://www.bbc.com/news/business-55170756)

Hurtado, Diego and Souza, Pablo. 2018. “Geoeconomic Uses of Global Warming: The ‘Green’ Technological Revolution and the Role of the Semi-Periphery.” Journal of World-Systems Research 24(1):123-150. https://doi.org/10.5195/jwsr.2018.700

Hurtado, Diego and Zubeldia, Lautaro. 2017. “El rol de las universidades públicas argentinas en el desarrollo económico.” Política Universitaria (4):24-33.

Ibáñez, Pablo. 2020. “La urgencia de las vacunas desata guerra de precios, lobby empresario y leyes a pedido”. El DiarioAr, December 19. Retrieved December 19, 2020 (https://www.eldiarioar.com/sociedad/coronavirus/guerra-precios-lobby-empresario-geopolitica_1_6518386.html)

Infobae. 2020a. “Ginés González García explicó por qué no se pudo cerrar la negociación con Pfizer por su vacuna contra el coronavirus”. December 15. Retrieved December 19, 2020 (https://www.infobae.com/politica/2020/12/15/coronavirus-en-argentina-gonzalez-garcia-explico-que-sucedio-en-la-negociacion-del-acuerdo-con-pfizer-por-la-vacuna/)

_____. 2020b. “La peligrosa campaña rusa para ridiculizar la vacuna de Oxford y evitar su éxito para combatir el COVID-19”, October 16. Retrieved November 4, 2020 (https://www.infobae.com/america/mundo/2020/10/16/la-peligrosa-campana-de-rusia-para-ridiculizar-la-vacuna-de-oxford-y-evitar-su-exito-para-combatir-el-covid-19/)

Ipsen, Anabelle. 2016. “Manufacturing a natural advantage: capturing place-based technology rents in the genetically modified corn seed industry.” Environmental Sociology 2(1):41-52. doi:10.1080/23251042.2015.1123598

Khor, Martin. 2008. “The World Trading System and Development Concerns” Pp. 215-259 in The Washington Consensus Reconsidered: Towards a New Global Governance, edited by Serra, Narcis and Stiglitz, Joseph. Oxford: Oxford University Press.

Krätke, Stefan. 2013. “Global Pharmaceutical and Biotechnology Firms’ Linkages in the World City Network”. Urban Studies 51(6):1196–1213. doi:10.1177/0042098013494420

Landesmann, Michael. 2015. “Ricardian and Schumpeterian rents: Fundamental ingredients for structural economic dynamics.” Pp. 186-197 in Resources, Production and Structural Dynamics, edited by Mauro, Baranzini, Claudia, Rotondi and Roberto, Scazzieri. Cambridge: Cambridge University Press.

Lavieri, Omar. 2020. “El infectólogo Fernando Polack con Infobae: ‘Hoy ya no es imposible prevenir o frenar al coronavirus’”. Infobae, December 15. Retrieved December 16, 2020 (https://www.infobae.com/tendencias/2020/12/11/el-infectologo-fernando-polack-con-infobae-hoy-ya-no-es-imposible-prevenir-o-frenar-al-coronavirus/)

Levine, Myron M. 2004. New generation vaccines. New York: London: Marcel Dekker; Taylor & Francis.

Lombardi, Vanina. 2020. “Los Costos ocultos de la vacuna”. Agencia TSS, October 8. Retrieved October 16, 2020 (http://www.unsam.edu.ar/tss/los-costos-ocultos-de-la-vacuna/)

Lloyd, Paulette, Mahutga, Matthew and De Leeuw, Jan. 2009. “Looking Back and Forging Ahead: Thirty Years of Social Network Research on the World-System.” Journal of World-Systems Research 15(1):48-85. https://doi.org/10.5195/jwsr.2009.335

Malerba, Franco and Orsenigo, Luigi. 2000. “Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening.” KITeS, Centre for Knowledge, Internationalization and Technology Studies, Universita' Bocconi, Milano, Italy, KITeS Working Papers.

_____. 2002. “Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: toward a history-friendly model.” Industrial and Corporate Change 11(4):667-703.

Martínez Piva Jorge, M. and Tripo, Francesco. 2019. “Innovación y propiedad intelectual: el caso de las patentes y el acceso a medicamentos.” Comisión Económica para América Latina y el Caribe (CEPAL).

Mazzucato, Mariana and Dosi, Giovanni. 2006. Knowledge Accumulation and Industry Evolution. Cambridge: Cambridge University Press.

Merkina, Natalia. 2009. “Technological catch-up or resource rents?” International Economics and Economic Policy 6(1):59–82.

Mulligan, Mark J., Lyke, Kirsten E., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Raabe, Vanessa, Bailey, Ruth, Swanson, Kena A., Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Özlem, Tompkins, Kristin R., Walsh, Edward. E., Frenck, Robert, Falsey, Ann, Dormitzer, Philip, Gruber, William, Şahin, Uğur, Jansen, Kathrin. U. 2020. “Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.” Nature 586(7830):589–593. https://doi.org/10.1038/s41586-020-2639-4

Navas, María Elena. 2020a. “Coronavirus: cómo son las 6 vacunas contra el virus que ya se están probando en humanos y qué países están ganando la carrera”. BBC, April 30. Retrieved October 14, 2020 (https://www.bbc.com/mundo/noticias-52472090)

_____. 2020b. “Vacuna contra la covid-19: por qué Brasil es considerado el ‘laboratorio perfecto’ para probarlas”. BBC, September 1. Retrieved October 11, 2020 (https://www.bbc.com/mundo/noticias-53951373)

O'Donnell, Carl. 2020. “Why Pfizer’s ultra-cold COVID-19 vaccine will not be at the local pharmacy any time soon”. Reuters, November 9. Retrieved December 19, 2020 (https://www.reuters.com/article/health-coronavirus-vaccines-distribution-idUSKBN27P2VP)

Orsi, Fabienne and Coriat, Benjamin. 2006. “The New Role and Status of Intellectual Property Rights in Contemporary Capitalism.” Competition & Change 10(2):162–179. doi:10.1179/102452906x104222

Página 12. 2020a. “Hacen una pausa en las pruebas de la vacuna de Oxford contra la Covid-19”, September 9. Retrieved September 16, 2020 (https://www.pagina12.com.ar/290760-hacen-una-pausa-en-las-pruebas-de-la-vacuna-de-oxford-contra?utm_medium=Echobox&utm_source=Facebook&fbclid=IwAR3ZvxrFT_doNxfi3XtXeIxLKyGUoNIGzH5XaDneGi5C0n_QtxmVDq7IlqU#Echobox=1599607406)

_____. 2020b. “La paciente que frenó a la vacuna de Oxford sería dada de alta en estas horas y esperan que no alargue los plazos”, September 9. Retrieved September 16, 2020 (https://www.pagina12.com.ar/291052-la-paciente-que-freno-a-la-vacuna-de-oxford-seria-dada-de-al)

Perfil. 2020. “Hugo Sigman: ‘Si la vacuna se aprueba se va a vender, sino, se va a tirar’”. August 13. Retrieved October 13, 2020 (https://www.perfil.com/noticias/ciencia/hugo-sigman-dijo-esta-fue-negociacion-entre-privados-ningun-gobierno-jugo-nungun-papel.phtml)

Pisano, Gary. 2006. The Governnance of Innovation: Vertical Integration and Collaborative Arrangement in the Biotechnology Industry. Cheltenhem, U.K and North Hampton, Mass.: Elgar.

Porta, Fernando, Santarcangelo, Juan and Schteingart, Daniel. 2017. “Cadenas globales de valor y desarrollo económico.” Revista Economía y Desafíos del Desarrollo 1(1):28-46.

Rabinovich, Gabriel and Geffner, Jorge. 2021. “Facing up to the COVID-19 pandemic in Argentina.” Nature Immunology 22:264-265. Retrieved March 3, 2021 (https://doi.org/10.1038/s41590-021-00873-w)

Rikap, Cecilia. 2019. “Asymmetric Power of the Core: Technological Cooperation and Technological Competition in the Transnational Innovation Networks of Big Pharma.” Review of International Political Economy 26(5):1-35.

Reyes, Francisco. 2020. “Argentina comenzará a probar la vacuna china desarrollada por Sinopharm contra COVID-19”, Infobae, September 7. Retrieved September 16, 2020 (https://www.infobae.com/salud/ciencia/2020/09/07/argentina-comenzara-a-probar-la-vacuna-china-desarrollada-por-sinopharm-contra-covid-19)

Roggero, Luciana. 2006. “La Salud Pública y las Vacunas. Calendario Nacional de Vacunación”. Departamento de Bioquímica Clínica. (Documento de trabajo inédito). Área Tecnología en Salud Pública. Asignatura en Salud Pública.

Romero, Nicolás. 2020. “Coronavirus: Fundación Huésped busca 3000 voluntarios para probar la vacuna china”, Página 12, September 9. Retrieved September 16, 2020 (https://www.pagina12.com.ar/290641-coronavirus-fundacion-huesped-busca-3000-voluntarios-para-pr)

Sanahuja, José. 2017. “Posglobalización y ascenso de la extrema derecha: crisis de hegemonía y riesgos sistémicos.” Pp. 41-77 in Seguridad Internacional y Democracia: guerras, militarización y fronteras, coordinated by Mesa, Manuela Madrid: CEIPAZ.

Santos Rutschman, Ana. 2020. “The COVID-19 Vaccine Race: Intellectual Property, Collaboration(s), Nationalism and Misinformation.” Washington University Journal of Law and Policy. Retrieved July 25, 2020 (https://ssrn.com/abstract=3656929)

Scazzieri, Roberto, Baranzini, Mauro and Rotondi, Claudia. 2015. “Resources, scarcitiesand rents: Technological interdependence and the dynamics of socio-economic structures.” Pp. 427-484 in Resources, Production and Structural Dynamics, edited by Mauro Baranzini, Claudia Rotondi and Roberto Scazzieri. Cambridge: Cambridge University Press.

Schlake, Thomas, Thess, Andreas, Fotin-Mleczek, Mariola and Kallen, Karl-Josef. 2012. “Developing mRNA-vaccine technologies.” RNA biology 9(11):1319–1330. Retrieved February 9, 2021 (https://doi.org/10.4161/rna.22269)

Servick, Kelly. 2020. “Meet the company that has just begun testing a coronavirus vaccine in the United States”. Science, March 25. Retrieved October 11, 2020 (https://www.sciencemag.org/news/2017/02/mysterious-2-billion-biotech-revealing-secrets-behind-its-new-drugs-and-vaccines)

Sicilia, Alberto. 2020. “Así está la carrera por la vacuna contra el coronavirus: además de la registrada por Rusia hay otras 6 en fase avanzada de prueba”, Página 12, August 11. Retrieved September 16, 2020 (https://www.pagina12.com.ar/284357-asi-esta-la-carrera-por-la-vacuna-contra-el-coronavirus-adem)

Smink, Veronica. 2020. “Coronavirus: cómo es el laboratorio argentino que va a producir la vacuna de la Universidad de Oxford y AstraZeneca para América Latina”, BBC, August 14. Retrieved September 16, 2020 (https://www.bbc.com/mundo/noticias-america-latina-53783657)

Sputnik V. 2020. “La primera vacuna registrada contra el COVID 19”. In: https://sputnikvaccine.com/esp/. Retrieved October 16, 2020.

Terlouw, Kees. 2003. “Semi-Peripheral Developments: From World-Systems to Regions.” Capitalism Nature Socialism 14(4):71-90. Retrieved March 3, 2021 (doi:10.1080/10455750308565547)

UBATEC and CAB. 2016. Biotecnología argentina al año 2030: llave estratégica para un modelo de desarrollo tecno-productivo. Buenos Aires: Ministerio de Ciencia, Tecnología e Innovación Productiva.

UNSAM. 2020. “Comienza el desarrollo de una vacuna argentina contra el nuevo Coronavirus”, Noticias Universidad Nacional de San Martín, June 23. Retrieved December 18, 2020 (https://noticias.unsam.edu.ar/2020/6/23/comienza-el-desarrollo-de-una-vacuna-argentina-contra-el-nuevo-coronavirus/)

UNL. 2020. “Científicos de la UNL buscan desarrollar una vacuna contra el COVID-19”, Noticias Universidad Nacional del Litoral, May 5. Retrieved December 18, 2020 (https://www.unl.edu.ar/noticias/news/view/cient%C3%ADficos_de_la_unl_buscan_desarrollar_vacuna_contra_el_covid-19#.X9zuldhKg2w)

Wallace, Robert G. 2016. Big Farms Make Big Flu: Dispatches on Influenza, Agribusiness, and the Nature of Science. U.S.: Monthly Review Press.

Wallerstein, Immanuel. 1974a. “The Rise and Future Demise of the World Capitalist System: Concepts for Comparative Analysis.” Comparative Studies in Society and History 16(4): 387-415.

_____. 1974b. “Dependence in an Interdependent World: The Limited Possibilities of Transformation within the Capitalist World Economy.” African Studies Review 17(1):1-26.

_____. 1976. “Semi-Peripheral Countries and the Contemporary World Crisis.” Theory and Society. 3(4):461-483.

_____. 2009. “Protection Networks and Commodity Chains in the Capitalist World-Economy.” Pp. 83-89 in Frontiers of Commodity Chain Research, Jennifer Bair, ed. Stanford: Stanford University Press.

WHO, UNICEF and World Bank. 2010. Vacunas e inmunización: situación mundial. Ginebra, Organización Mundial de la Salud.

WTO Web. “The WTO's Pharma Agreement”. Retrieved July 1, 2021 (https://www.wto.org/english/tratop_e/pharma_ag_e/pharma_agreement_e.htm)

Xia Shengli, Duan Kai, Zhang Yuntao, et al. 2020. “Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.” JAMA 324(10):951–960. doi:10.1001/jama.2020.15543

Xia, Shengli, Zhang, Yuntao, Wang, Yanxia, et al. 2021. “Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.” The Lancet 21(1):39-51. https://doi.org/10.1016/S1473-3099(20)30831-8

Zubeldia, Lautaro. 2020. “Producción nacional de vacunas: ¿una meta imposible?” Revista Ciencia Hoy 28(168):15-21.

Downloads

Published

2021-08-14

How to Cite

Blinder, D., Zubeldía, L. ., & Surtayeva, S. . (2021). Covid-19 and Semi-Periphery: Argentina and the Global Vaccines Research and Development. Journal of World-Systems Research, 27(2), 494–521. https://doi.org/10.5195/jwsr.2021.1049

Issue

Vol. 27 No. 2 (2021): Summer/Autumn 2021

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site;
    with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
  4. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
  5. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
  6. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
  7. The Author represents and warrants that:
    1. the Work is the Author’s original work;
    2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
    3. the Work is not pending review or under consideration by another publisher;
    4. the Work has not previously been published;
    5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
    6. the Work contains no libel, invasion of privacy, or other unlawful matter.
  8. The Author agrees to indemnify and hold Publisher harmless from Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Revised 7/16/2018. Revision Description: Removed outdated link.